Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). CONCLUSIONS: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Cited by
Items 601–700 of 1,001
The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE
Goto, S., Turpie, A. G. G., Farjat, A. E., Weitz, J. I., Haas, S. K., Ageno, W., Goldhaber, S. Z., Angchaisuksiri, P., Kayani, G., MacCallum, P., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.05.007 · Cited by 25
Piazza, G., Mani, V., Goldhaber, S. Z., Grosso, M. A., Mercuri, M., Lanz, H. J., Schussler, S., Hsu, C., Chinigo, A., Ritchie, B., et al. (2016) · Vascular Medicine · doi:10.1177/1358863x16645853 · Cited by 18
Diretrizes sobre trombose venosa profunda da Sociedade Brasileira de Angiologia e Cirurgia Vascular
Sobreira, M. L., Marques, M. A., Paschôa, A. F., Ribeiro, A. J. A., Casella, I. B., Burihan, M. C., Matielo, M. F., Soares, R. D. A., de Araújo, W. J. B., Joviliano, E. É., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202301071 · Cited by 29
“A dose diária é de 60 mg, em dose única diária, iniciada após 5 dias de tratamento com HNF ou HBPM 76,77 .”
BackgroundClinical impact and course of major bleeding with edoxaban versus vitamin K antagonists
Brekelmans, M. P. A., Bleker, S. M., Bauersachs, R. M., Boda, Z., Buller, H. R., Choi, Y., Gallus, A. S., GROSSO, M. A., Middeldorp, S., Oh, D., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-11-0892 · Cited by 19
“The protocol of the Hokusai-VTE study pre-specified treatment strategies that could be applied for bleeding events (9, 16).”
BackgroundMethodResultWeitz, J. I., & Chan, N. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1679906 · Cited by 18
Lapumnuaypol, K., DiMaria, C. N., & Chiasakul, T. (2019) · QJM · doi:10.1093/qjmed/hcz127 · Cited by 18
Ebraheem, M. S., Alzahrani, I., Crowther, M. A., Rochwerg, B. N., & Almakadi, M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14949 · Cited by 22
Rivera‐Caravaca, J. M., Harrison, S. L., Buckley, B. J. R., Fazio‐Eynullayeva, E., Underhill, P., Marín, F. R., & Lip, G. Y. H. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01368-6 · Cited by 18
Direct Oral Anticoagulants and Coronary Artery Disease
Choxi, R., Kapoor, K., Mackman, N., & Jovin, I. S. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317171 · Cited by 21
Williams, M. A., Ahuja, T., Raco, V., Papadopoulos, J., Green, D., Yuriditsky, E., & Arnouk, S. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02641-5 · Cited by 18
Wysokiński, W. E., Houghton, D. E., Vlazny, D. T., Ashrani, A. A., Froehling, D. A., Kamath, P. S., Meverden, R. A., Hodge, D. O., Peterson, L. G., Lang, T. R., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.11.005 · Cited by 18
Hiramoto, K., Akita, N., Nishioka, J., & Suzuki, K. (2023) · TH Open · doi:10.1055/s-0042-1758855 · Cited by 18
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art
Monaco, G., Bucherini, L., Stefanini, B., Piscaglia, F., Foschi, F. G., & Ielasi, L. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i33.4962 · Cited by 21
“Despite cirrhotic patients have been excluded from phase III trials of DOACs for atrial fibrillation[65-68] and venous thromboembolism[69-72], several studies on their use in this cohort of patients have been published, demonstrating DOACs safety in patients with compensated liver disease…”
Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants
Laliberté, F., Coleman, C. I., Bookhart, B., Lefèbvre, P., Cloutier, M., Damaraju, C. V., Schein, J. R., & Kaatz, S. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.915801 · Cited by 20
Verso, M., Agnelli, G., & Prandoni, P. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1233-5 · Cited by 19
“term treatment of VTE showed non-inferior efficacy with a potentially better safety profile for the new oral anticoagulants (NOACs) in comparison to the conventional anticoagulation [18–24].”
BackgroundEfficacy and safety of direct oral anticoagulants after pulmonary embolism: A meta-analysis
Vedovati, M. C., Becattini, C., Germini, F., & Agnelli, G. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.08.136 · Cited by 20
“The analysis based on the single-drug approach [3,6] or the heparin/direct oral anticoagulants approach [2,4,5] showed an OR of 1.”
BackgroundMethodUresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.10.008 · Cited by 40
Riess, H. B., Habbel, P., Jühling, A., Sinn, M., & Pelzer, U. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i3.258 · Cited by 19
Hernandez, C. M. R., Oo, T. H., & García‐Perdomo, H. A. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1434-4 · Cited by 18
Direct oral anticoagulants in the treatment of pulmonary embolism
Eldredge, J. B., & Spyropoulos, A. C. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1364227 · Cited by 21
“Evidence related to treatment of cancerrelated PE with DOACs is limited, although 3% to 9% of patients included in the phase 3 VTE treatment trials of the 4 DOACs had active cancer or a history of cancer [22, 23, 25, 29, 32].”
BackgroundMethodInfluentialCancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
Smrke, A., & Gross, P. L. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00142 · Cited by 21
“Trial Anticoagulant Recurrent vTe Major bleeding N % N % Randomized controlled trial ONCENOX (12) Enoxaparin bridging to warfarin 3/30 10 1/34 2.9 Enoxaparina 2/29 6.9 2/31 6.5 Enoxaparinb 2/32 6.3 4/36 11.1 LITE (15, 16, 32, 33) Usual care (IV heparin or warfarin) 16/100 16* 7/100 7 Tinzaparin (175 U/kg/day) 7/100 7*…”
BackgroundInfluentialVenous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants
Vedovati, M. C., Giustozzi, M., & Becattini, C. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.031 · Cited by 18
Woller, S. C., Stevens, S. M., Johnson, S. A., Bledsoe, J. R., Galovic, B., Lloyd, J. F., Wilson, E. L., Armbruster, B. P., & Evans, R. S. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12208 · Cited by 21
Nakamura, M., Yamada, N., Asamura, T., Shiosakai, K., & Uchino, K. (2020) · Circulation Reports · doi:10.1253/circrep.cr-19-0127 · Cited by 21
Frère, C., Crichi, B., Lejeune, M., Spano, J., & Janus, N. (2020) · Cancers · doi:10.3390/cancers12040917 · Cited by 22
Leven, C., Hoffmann, C., Roche, C., Couturaud, F., Thereaux, J., & Lacut, K. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12587 · Cited by 19
Meredith, T., Schnegg, B., & Hayward, C. (2020) · Artificial Organs · doi:10.1111/aor.13848 · Cited by 18
Desai, R. J., Koipallil, G. K., Thomas, N., Mhaskar, R. S., Visweshwar, N., Laber, D. A., Patel, A. K., & Jaglal, M. V. (2020) · Scientific Reports · doi:10.1038/s41598-020-75863-3 · Cited by 19
Lachant, D. J., Bach, C., Fe, A., White, R. J., & Lachant, N. A. (2020) · ERJ Open Research · doi:10.1183/23120541.00554-2020 · Cited by 19
Chen, X., Liu, Y., Furukawa, N., Jin, D., Savage, G. P., Stafford, D. W., Suhara, Y., Williams, C. M., & Tie, J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15209 · Cited by 18
Kabrhel, C., Vinson, D. R., Mitchell, A. M., Rosovsky, R. P. G., Chang, A. M., Hernandez‐Nino, J., & Wolf, S. J. (2021) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12588 · Cited by 19
Li, M., Li, J., Wang, X., Xu, H., Wang, Q., Xie, S., Yan, P., Tian, J., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957.pub3 · Cited by 26
Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs)
Werth, S., Breslin, T., NíAinle, F., & Beyer‐Westendorf, J. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0123-6 · Cited by 20
Direct oral anticoagulants: integration into clinical practice
Cowell, R. P. W. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-132474 · Cited by 23
Prisco, D., Tufano, A., Cenci, C., Pignatelli, P., Santilli, F., Minno, G. D., & Perticone, F. (2018) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1956-1 · Cited by 19
“As far as DOACs are concerned, the anti-Xa edoxaban is the only one that has been studied in the setting of cancer VTE treatment at a reduced dose of 30 mg for patients with impaired renal function in the Hokusai VTE Cancer study [87]; hence, it could be reasonable to use a reduced dose of edoxaban in patients with Cr…”
BackgroundExpanding use of new oral anticoagulants
Weitz, J. I. (2014) · F1000Prime Reports · doi:10.12703/p6-93 · Cited by 18
“In patients with acute VTE, dabigatran, rivaroxaban, apixaban, and edoxaban were compared with conventional treatment in the RE-COVER I and II, EINSTEINDVT and -PE, AMPLIFY, and Hokusai-VTE trials, respectively [19–24].”
MethodDirect oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism
Fontana, P., Goldhaber, S. Z., & Bounameaux, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu027 · Cited by 22
Brandão, G. M. S., Cândido, R. C. F., Rollo, H. A., Sobreira, M. L., & Junqueira, D. R. (2018) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.005518 · Cited by 33
Shah, R., Sheikh, N., Mangwani, J., Morgan, N. J., & Khairandish, H. (2020) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2020.08.005 · Cited by 19
Platelet and HIV Interactions and Their Contribution to Non-AIDS Comorbidities
Awamura, T., Nakasone, E. S., Gangcuangco, L. M. A., Subia, N., Bali, A.-J., Chow, D. C., Shikuma, C. M., & Park, J. (2023) · Biomolecules · doi:10.3390/biom13111608 · Cited by 22
“As PLWH were excluded from the initial studies that evaluated these direct Xa inhibitors for the management of VTE [173–176], there is limited data on these agents’ use in PLWH.”
BackgroundTalerico, R., Pola, R., Klok, F. A., & Huisman, M. V. (2024) · TH Open · doi:10.1055/s-0043-1776989 · Cited by 20
Gallus, A. S., Sanders, P. W., Thompson, J. R., Agnelli, G., Buller, H. R., Cohen, A. T., Ramacciotti, E., Weitz, J. I., & Raskob, G. E. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-09-0752 · Cited by 19
Senoo, K., Kondo, Y., Miyazawa, K., Isogai, T., Chun, Y., & Kobayashi, Y. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.07.007 · Cited by 19
Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment
Tran, E., Duckett, A. A., Fisher, S., & Bohm, N. M. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1487-z · Cited by 18
Hurwitz, A., Massone, R., & Lopez, B. L. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.08.012 · Cited by 17
Chopard, R., Serzian, G., Humbert, S., Falvo, N., Morel-Aleton, M., Bonnet, B., Napporn, G., Kalbacher, E., Obert, L., Degano, B., et al. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1690-6 · Cited by 18
Thrombophilia evaluation in pulmonary embolism
Stern, R. M., Al-Samkari, H. T., & Connors, J. M. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000668 · Cited by 20
“As was seen in a compelling subgroup analysis of the Hokusai VTE trial, is possible that DOACs may be better than warfarin to prevent VTE recurrence in patients with pulmonary embolism leading to right ventricular dysfunction [31].”
Beenen, L. F. M., Scheres, L. J. J., Stoker, J., & Middeldorp, S. (2020) · ERJ Open Research · doi:10.1183/23120541.00163-2019 · Cited by 17
Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism
Trujillo‐Santos, J., Beroiz, P., Moustafa, F., Álvarez, A. A., Morejon, E., López-Reyes, R., Casado, I., Porras, J. A., Flores, K., López-Núñez, J. J., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.035 · Cited by 18
Illig, K. A., & Gober, L. (2021) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2021.07.011 · Cited by 20
Chen, J., Lv, M., Wu, S., Jiang, S., Xu, W., Qian, J., Chen, M., Fang, Z., Zeng, Z., & Zhang, J. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2021.10.054 · Cited by 21
Anticoagulant therapy after venous thromboembolism and 10-year mortality
Larsen, T. B., Lip, G. Y. H., & Gorst‐Rasmussen, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.190 · Cited by 17
Cancer-Associated Venous Thromboembolism
Elewa, H. F., Elrefai, R., & Barnes, G. D. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0445-y · Cited by 17
Kobayashi, H., Akamatsu, Y., Kumagai, K., Kusayama, Y., Ishigatsubo, R., Mitsuhashi, S., Kobayashi, A., Aratake, M., & Saito, T. (2016) · Knee Surgery Sports Traumatology Arthroscopy · doi:10.1007/s00167-016-4065-6 · Cited by 17
“Edoxaban (Lixiana; Daiichi Sankyo, Tokyo, Japan) is an oral, direct factor Xa inhibitor used for the prevention and treatment of thromboembolic events [6, 28].”
BackgroundTesta, S., Dellanoce, C., Paoletti, O., Cancellieri, E., Morandini, R., Tala, M., Zambelli, S., & Legnani, C. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.01.008 · Cited by 17
Dager, W. E., & Hellwig, T. R. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150960 · Cited by 16
Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome
Efthymiou, M., Gates, C., Isenberg, D. A., & Cohen, H. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597902 · Cited by 17
Su, X., Yan, B., Wang, L., Cheng, H., & Chen, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-048619 · Cited by 17
Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis
Tadokoro, T., Tani, J., Manabe, T., Takuma, K., Nakahara, M., Oura, K., Mimura, S., Fujita, K., Nomura, T., Morishita, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60235-y · Cited by 18
“Two recent studies 26,27 concluded that edoxaban (administered once daily after initial treatment with heparin) could be an alternative to warfarin in patients with venous thromboembolism.”
BackgroundHentschel, V. A.-T., Du, S., Zolfaghari, S., Krämer, R., Weiss, C., Krämer, B. K., Wehling, M., & Harenberg, J. (2014) · Hämostaseologie · doi:10.5482/hamo-14-08-0036 · Cited by 16
Konstantinides, S., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D. A., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M. J. C., Kucher, N., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.12.002 · Cited by 25
Dosing of Target-Specific Oral Anticoagulants in Special Populations
Morrill, A. M., Ge, D., & Willett, K. C. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015591846 · Cited by 16
“The Hokusai-VTE Investigators excluded patients with a CrCl less than 30 mL/min and reduced the dose by 50% in patients with a CrCl of 30-50 mL/min.(34) Despite using lower doses, there was no difference in the rate of VTE, but a 2.”
BackgroundRoberts, K. M., Knight, T., Padilla‐Tolentino, E., Murthy, M. S., & Peterson, E. J. (2015) · Thrombosis · doi:10.1155/2015/414523 · Cited by 17
Advanced Management Options for Massive and Submassive Pulmonary Embolism
Malik, S., Bhardwaj, A., Eisen, M., & Gandhi, S. (2016) · US Cardiology Review · doi:10.15420/usc.2016.10.1.30 · Cited by 18
Pathways for outpatient management of venous thromboembolism in a UK centre
Condliffe, R. A. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0120-2 · Cited by 17
Pulmonary embolism: Care standards in 2018
Borohovitz, A., Weinberg, M. D., & Weinberg, I. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.12.005 · Cited by 16
“In this study 30%of patients presentedwith intermediate risk PE (30%).(47) Other studies, while not excluding patients according to their risk category, did not report on PE severity.”
Badreldin, H. A. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1661-y · Cited by 18
Ikeda, S., Koga, S., Yamagata, Y., Eguchi, M., Sato, D., Muroya, T., Yonekura, T., Tsuneto, A., Yoshimuta, T., Koide, Y., et al. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.03.006 · Cited by 18
Yhim, H., Choi, W.-I., Kim, S., Nam, S.-H., Kim, K. H., Mun, Y., Oh, D., Hwang, H.-G., Lee, K., Song, E., et al. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.097 · Cited by 16
“Although the pivotal phase III trials testing DOACs included cancer patients, the results of these trials [9-13] and subsequent subgroup analysis [14-17] have been underpowered by the small number of cancer patients and the heterogeneity in definition of cancer for the trials [18].”
Yan, Y., Zhang, C., Shen, L., Su, Y.-J., Liu, X., Wang, L., & Gu, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00575 · Cited by 16
on behalf of the ETNA-VTE-Europe investigators, Cohen, A. T., Ay, C., Hainaut, P., Decousus, H., Hoffmann, U., Gaine, S., Coppens, M., da Silva, P. M., Jiménez, D., et al. (2018) · Thrombosis Journal · doi:10.1186/s12959-018-0163-7 · Cited by 16
Beyer‐Westendorf, J., Klamroth, R., Kreher, S., Länger, F. P., Matzdorff, A. C., & Riess, H. B. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0031 · Cited by 17
Farge, D., Maignan, C. L., Doucet, L. S., & Frère, C. (2019) · Thrombosis Research · doi:10.1016/s0049-3848(19)30367-6 · Cited by 20
Papakonstantinou, P. Ε., Tsioufis, C. P., Konstantinidis, D., Iliakis, P., Leontsinis, I., & Tousoulis, D. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200420150517 · Cited by 17
Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese
Doucette, K., Latif, H., Vakiti, A., Tefera, E. A., Patel, B. A., & Fitzpatrick, K. (2020) · Advances in Hematology · doi:10.1155/2020/3890706 · Cited by 16
Li, X., Hu, Y., Lin, P., Zhang, J., Tang, Y., Yi, Q., Liang, Z., Zhou, H., & Wang, M. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1355-3549 · Cited by 16
Xu, J.-X., Wang, G., Chen, X., Shen, Y., Wang, X., & Wang, H. (2023) · Thrombosis Journal · doi:10.1186/s12959-023-00456-9 · Cited by 16
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Masini, M., Toma, M., Spallarossa, P., Porto, I., & Ameri, P. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01428-y · Cited by 18
Direct oral anticoagulants: a guide for daily practice
Fontana, P., Robert‐Ebadi, H., Bounameaux, H., Boehlen, F., & Righini, M. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14286 · Cited by 22
How we treat bleeding associated with direct oral anticoagulants.
Marano, G., Vaglio, S., Pupella, S., Liumbruno, G. M., & Franchini, M. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2016.0180-15 · Cited by 18
Evaluation of anticoagulation selection for acute venous thromboembolism
Badreldin, H. A., Nichols, H., Rimsans, J., & Carter, D. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1417-5 · Cited by 16
Kawano, H., & Maemura, K. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.7314 · Cited by 16
“VTE, including those with severe pulmonary embolism (5).”
BackgroundManagement of venous thromboembolism in myeloproliferative neoplasms
Barbui, T., & Stefano, V. D. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000312 · Cited by 17
Uppuluri, E. M., Burke, K. R., Haaf, C. M., & Shapiro, N. L. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217730129 · Cited by 16
Reduced cardiac function and risk of venous thromboembolism in Asian countries
Zhu, R., Hu, Y., & Tang, L. V. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0135-3 · Cited by 18
“could decreased bleeding events significantly [47].”
ResultManagement of pulmonary embolism: recent evidence and the new European guidelines
Konstantinides, S., & Torbicki, A. (2014) · European Respiratory Journal · doi:10.1183/09031936.00180414 · Cited by 19
Anticoagulation therapy in 2015: where we are and where we are going
Weitz, J. I. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1194-6 · Cited by 15
“apixaban, and edoxaban were compared with conventional treatment in the RE-COVER I and II, EINSTEIN-DVT and EINSTEIN-PE, AMPLIFY, and Hokusai-VTE trials, respectively [20–25].”
MethodAthanazio, R. A., Ceresetto, J. M., Marfil‐Rivera, L. J., Cesarman-Maus, G. N., Gálvez, K., Marques, M. A., Tabares, A. H., Santacruz, C. A. O., Santini, F. C., Corrales, L., et al. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296221082988 · Cited by 16
Lawal, O. D., Aronow, H. D., Hume, A. L., Shobayo, F. O., Matson, K. L., Barbour, M. M., Zhang, Y., & Wen, X. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102293 · Cited by 19
Zalpour, A., & Oo, T. H. (2015) · Advances in Hematology · doi:10.1155/2015/920361 · Cited by 15
Alberio, L. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.002 · Cited by 16
Minno, M. N. D. D., Ambrosino, P., Lupoli, R., Minno, A. D., & Dentali, F. (2015) · PubMed · doi:10.2450/2014.0184-14 · Cited by 19
Kataruka, A., Kong, X., Haymart, B., Kline-Rogers, E. M., ALMANY, S. L., Kozłowski, J., Krol, G. D., Kaatz, S., McNamara, M. W., Froehlich, J. B., et al. (2017) · Vascular Medicine · doi:10.1177/1358863x16682863 · Cited by 25
Terleira‐Fernández, A. I., Lecumberri, R., Suárez‐Gea, M. L., Calvo, G., Vargas, E., & Gómez‐Outes, A. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1642644 · Cited by 17
Weir, M. R., & Kreutz, R. H. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.06.018 · Cited by 16
Nazha, B., Pandya, B., Spyropoulos, A. C., & Kessler, C. M. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1673690 · Cited by 16
Lutsey, P. L., Norby, F. L., Zakai, N. A., MacLehose, R. F., Chen, L. Y., Shah, S., Datta, Y. H., & Alonso, Á. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541445 · Cited by 16
Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
Khachatryan, T., Hauschild, C., Hoff, J., Contractor, T. A., Khachatryan, A., Tran, H. N., Matsuo, B., Jacobson, A. K., & Hilliard, A. A. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00344-6 · Cited by 15
“The recommendation for the treatment of DVT or PE is 60 mg daily for CrCl > 50 mL/min and patient weight > 60 kg or 30 mg daily for CrCl 15–50 mL/min or patient weight ≤ 60 kg or for those receiving P-gp inhibitors (specific P-gp inhibitors in the Hokusai-VTE trial included verapamil and quinidine or the short-term co…”
BackgroundMethodFaqah, A., Sheikh, H. S., Bakar, M. A., Tayyaab, F., & Khawaja, S. (2020) · Thrombosis Journal · doi:10.1186/s12959-020-00221-2 · Cited by 15
Mai, V., Marceau-Ferron, E., Bertoletti, L., Lacasse, Y., Bonnet, S., Lega, J., & Provencher, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105317 · Cited by 19
Metadata
- Authors
- The Hokusai-VTE Investigators
- Corresponding author
- The Hokusai-VTE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-10
- Volume
- 369
- Issue
- 15
- Pages
- 1406-1415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160625453
- Cited by
- 1,869
- References
- 25
- Citations by year
- 2026: 52 · 2025: 75 · 2024: 112 · 2023: 104 · 2022: 116 · 2021: 128 · 2020: 179 · 2019: 170 · 2018: 190 · 2017: 173 · 2016: 210 · 2015: 173 · 2014: 161 · 2013: 25
- FWCI
- 165.78
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, venous thromboembolism, factor Xa inhibitors, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, non-inferiority, bleeding risk, right ventricular dysfunction, N-terminal pro-brain natriuretic peptide, anticoagulation, heparin, renal dysfunction, body weight
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Warfarin, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.